{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:41:15Z","timestamp":1793832075391,"version":"4.6.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ophtha.2020.11.011","type":"journal-article","created":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T17:21:04Z","timestamp":1605460864000},"page":"1050-1059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":339,"title":["Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion\u2013Related Events with Brolucizumab"],"prefix":"10.1016","volume":"128","author":[{"given":"Jordi","family":"Mon\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil K.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn J.","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5616-3579","authenticated-orcid":false,"given":"Ramin","family":"Tadayoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Albini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4438-9535","authenticated-orcid":false,"given":"Jean-Francois","family":"Korobelnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana K.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pruente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy G.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Heier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2020.11.011_bib1","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1984.01040031330019","article-title":"Age-related macular degeneration and blindness due to neovascular maculopathy","volume":"102","author":"Ferris","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.11.011_bib2","first-page":"514","article-title":"New treatment modalities for neovascular age-related macular degeneration","volume":"6","author":"Schlottmann","year":"2017","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.ophtha.2020.11.011_bib3","first-page":"CD012208","article-title":"Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration","volume":"5","author":"Li","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ophtha.2020.11.011_bib4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ophtha.2020.11.011_bib5","first-page":"1522","article-title":"Comparative safety of bevacizumab, ranibizumab, and aflibercept for treatment of neovascular age-related macular degeneration (AMD): a systematic review and network meta-analysis of direct comparative studies","volume":"9","author":"Plyukhova","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.ophtha.2020.11.011_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197670","article-title":"The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective","volume":"13","author":"van Asten","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ophtha.2020.11.011_bib7","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.oret.2018.04.018","article-title":"Systemic safety in ranibizumab-treated patients with neovascular age-related macular degeneration: a patient-level pooled analysis","volume":"2","author":"Zarbin","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ophtha.2020.11.011_bib8","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/bjophthalmol-2018-312453","article-title":"Safety of 5914 intravitreal ziv-aflibercept injections","volume":"103","author":"Singh","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.11.011_bib9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.oret.2016.12.015","article-title":"Serious AEs with bevacizumab or ranibizumab for age-related macular degeneration: meta-analysis of individual patient data","volume":"1","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ophtha.2020.11.011_bib10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.survophthal.2010.08.006","article-title":"Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease","volume":"56","author":"Tolentino","year":"2011","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.11.011_bib11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.11.011_bib12","series-title":"Beovu 120 mg\/ml solution for injection in pre-filled syringe - Summary of Product Characteristics","year":"2020"},{"key":"10.1016\/j.ophtha.2020.11.011_bib14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.11.011_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: 96-Week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.11.011_bib16","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.11.011_bib17","doi-asserted-by":"crossref","first-page":"100687","DOI":"10.1016\/j.ajoc.2020.100687","article-title":"Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations","volume":"18","author":"Jain","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.ophtha.2020.11.011_bib19","author":"Novartis"},{"key":"10.1016\/j.ophtha.2020.11.011_bib20","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2020.11.011_bib21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/09286586.2015.1090004","article-title":"Severe ocular inflammation following ranibizumab or aflibercept injections for age-related macular degeneration: a retrospective claims database analysis","volume":"23","author":"Souied","year":"2016","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.ophtha.2020.11.011_bib22","author":"Do"},{"key":"10.1016\/j.ophtha.2020.11.011_bib23","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.ophtha.2016.05.016","article-title":"Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid","volume":"123","author":"Jaffe","year":"2016","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642020310757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642020310757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:10:41Z","timestamp":1758982241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642020310757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0161642020310757"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2020.11.011","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739074013.793591118","asserted-by":"object"}]},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion\u2013Related Events with Brolucizumab","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2020.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of OphthalmologyThis is an open access article under the CC BY-NC-ND license (<inter-ref xlink: href=http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/>http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/<\/inter-ref>).","name":"copyright","label":"Copyright"}]}}